Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 1.00 |
| ▸ | DRD4 | P21917 | 1/20 | 1.00 |
| ▸ | DRD2 | P14416 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.52 |
| ▸ | HTR1A | P08908 | 1/20 | 0.52 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.52 |
| ▸ | DRD1 | P21728 | 1/20 | 0.52 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.52 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.52 |
| ▸ | DRD3 | P35462 | 1/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6907364 | 1.00 | HTR2A (1.00) | HTR2ADRD4DRD2MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL8552262 | 0.99 | HTR2A (0.98) | HTR2ADRD4DRD2MEN1KMT2A | |
| Bromide SCHEMBL8553366 | 0.95 | HTR2A (0.91) | HTR2ADRD4DRD2MEN1KMT2A | |
| SCHEMBL8552863 | 0.93 | HTR2A (0.87) | HTR2ADRD4DRD2MEN1KMT2A | |
| SCHEMBL3726273 | 0.89 | HTR2A (0.79) | HTR2ADRD4DRD2MEN1KMT2A | |
| SCHEMBL13041313 | 0.86 | DRD4 (0.75) | HTR2ADRD4DRD2MEN1KMT2A | |
| SCHEMBL8552184 | 0.76 | DRD4 (0.61) | HTR2ADRD4DRD2MEN1KMT2A | |
| SCHEMBL8558550 | 0.75 | HTR2A (0.59) | HTR2ADRD4DRD2 | |
| SCHEMBL8556407 | 0.74 | DRD4 (0.59) | HTR2ADRD4MEN1KMT2ATSHR | |
| SCHEMBL8553513 | 0.74 | HTR2A (0.59) | HTR2ADRD4DRD2HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020094986-A1 | Combination treatment for depression, anxiety and psychosis | PFIZER INC | 2002-07-18 | — | — | US | disclosed |
| EP-1213031-A2 | Combination treatment for depression, anxiety and psychosis comprising an antidepressant and/or anxiolytic and a D4 receptor antagonist | Pfizer Products Inc. (US) | 2002-06-12 | — | — | EP | disclosed |
| EP-0816362-A1 | THIAZOLE DERIVATIVES | TAISHO PHARMACEUTICAL CO. LTD (JP) | 1998-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020094986-A1 | Combination treatment for depression, anxiety and psychosis | HTR4, CHRNA4, GRM4 | HTR2A 63/4885DRD4 4/4885DRD2 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.